Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stake Trimmed by Aquatic Capital Management LLC

Aquatic Capital Management LLC trimmed its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 68.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,246 shares of the medical device company's stock after selling 46,254 shares during the quarter. Aquatic Capital Management LLC's holdings in Tandem Diabetes Care were worth $765,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of TNDM. AlphaQuest LLC grew its position in shares of Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after purchasing an additional 541 shares in the last quarter. Jones Financial Companies Lllp increased its position in Tandem Diabetes Care by 195.8% in the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after purchasing an additional 748 shares during the last quarter. Assetmark Inc. grew its position in Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after acquiring an additional 535 shares in the last quarter. McIlrath & Eck LLC bought a new stake in Tandem Diabetes Care during the third quarter worth approximately $52,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares during the last quarter.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the business's stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Stifel Nicolaus reduced their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Barclays lowered their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. The Goldman Sachs Group dropped their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Robert W. Baird decreased their target price on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a research note on Thursday, May 1st. Finally, Canaccord Genuity Group raised their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Tandem Diabetes Care presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.81.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded up $0.36 on Wednesday, reaching $21.68. The company's stock had a trading volume of 218,455 shares, compared to its average volume of 1,496,549. Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.69. The stock has a market capitalization of $1.44 billion, a P/E ratio of -11.20 and a beta of 1.47. The stock's 50-day moving average is $18.55 and its two-hundred day moving average is $28.38. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company's revenue for the quarter was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) EPS. As a group, sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.